Korsana Biosciences, Inc. lost $1.11 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Korsana Biosciences, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$1.11
YoYn/m
Ticker history: CYCN became
KRSA
(Korsana Biosciences, Inc.) on .
Earlier news and filings retain their original names and dates.
View CYCN history.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Korsana Biosciences, Inc. lost $1.11 per diluted share in fiscal year 2025.
Korsana Biosciences, Inc. (KRSA) reported a loss of $1.21 per diluted share in fiscal year 2024 and a loss of $1.11 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Across the 8 fiscal years this page covers, Korsana Biosciences, Inc. (KRSA) diluted earnings per share went from -$4.21 in fiscal year 2018 to -$1.11 in fiscal year 2025.
Korsana Biosciences, Inc. (KRSA) reported -$3.19 in diluted earnings per share in Q3 2026.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Korsana Biosciences, Inc. (KRSA) reported on that line in every period on record.
